Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod

Journal of Investigative Dermatology

Volumn 122, Issue 5, 2004, Pages 1266-1276

  Schön, Michael P ^a,b   Wienrich, B Gregor ^a,b   Drewniok, Claudia ^a,b   Bong, Anne B ^b   Eberle, Jürgen ^c   Geilen, Christoph C ^c   Gollnick, Harald ^b   Schön, Margarete ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Bcl 2; Imiquimod; Immune response modifier; Malignant melanoma

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CELL RECEPTOR; DEATH RECEPTOR; IMIQUIMOD; IMMUNE RESPONSE MODIFIER; PROTEIN BCL 2; RESIQUIMOD; TOPICAL AGENT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN METASTASIS;

EID: 2442555760     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22528.x     Document Type: Article

References (47)

1. Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R: The complexity of TNF-related apoptosis-inducing ligand. Ann NY Acad Sci 926:52-63, 2000
2. Ariza ME, Broome-Powell M, Lahti JM, Kidd VJ, Nelson MA: Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases. J Biol Chem 274:28505-28513, 1999
3. Armstrong BK, Kricker A: Cutaneous melanoma. Cancer Surveys 19:219-240, 1994
4. Bayaert R, Kidd VJ, Cornelis S, et al: Cleavage of PITSLRE kinases by ICE/CASP-1 and CPP32/CASP-3 during apoptosis induced by tumor necrosis factor. J Biol Chem 272:11694-11697, 1997
5. Bean MA, Bloom BR, Herberman RB, Old LJ, Oettgen HF, Klein G, Terry WD: Cell-mediated cytotoxicity for bladder carcinoma: Evaluation of a workshop. Cancer Res 35:2902-2913, 1975
6. Becker JC, Kämpgen E, Bröcker E: Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 25:503-508, 2000
7. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H: Imiquimod, a novel immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205:135-138, 2002
8. Bruggen J, Macher E, Sorg C: Expression of surface antigens and its relation to parameters of malignancy in human malignant melanoma. Cancer Immunol Immunother 10:121-127, 1981
9. Burns R, Ferbel B, Tomai M, Miller R, Gaspari A: The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans cells. Clin Immunol 94:13-23, 2000
10. Chang AE, Karnell LH, Menck HR: The national cancer database report of cutaneous and noncutaneous melanoma. Cancer 78:1664-1668, 1998
11. Cryns V, Yuan J: Proteases to die for. Genes Dev 12:1551-1570, 1999
12. Dirsch VM, Stuppner H, Vollmar AM: Helenalin triggers a CD95 death receptor-independent apoptosis that is not affected by overexpression of Bcl-XL or Bcl-2. Cancer Res 61:5817-5823, 2001
13. Franco AV, Zhang XD, van Berkel E, et al: The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of malignant melanoma. J Immunol 166:5337-5345, 2001
14. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP: In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 51:1417-1423, 1973
15. Gibson SJ, Imbertson LM, Wagner TL: Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 15:537-645, 1995
16. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161: 2833-2840, 1998
17. Helmbach H, Sinha P, Schadendorf D: Human melanoma: Drug resistance. Recent Results Cancer Res 161:93-110, 2003
18. Hemmi H, Kaisho T, Takeuchi O, et al: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200, 2002
19. Holzmann B, Lehmann JM, Ziegler-Heitbrock HW, Funke I, Riethmüller G, Johnson JP: Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen. Int J Cancer 41:542-547, 1988
20. Hussein MR, Haemel AK, Wood GS: Apoptosis and melanoma: Molecular mechanisms. J Pathol 199:275-288, 2003
21. Imbertson LM, Beaurline JM, Couture AM, et al: Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 110:734-739, 1998
22. Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49, 2000
23. Megyeri K, Au W-C, Rosztoczy I: Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by sendai virus utilize similar signal transaction pathways. Mol Cell Biol 15:2207-2218, 1995
24. Miller RL, Birmachu W, Gibson S: Cytokine induction by imiquimod, preclinical results and pharmacology. Chemother J 4:148-149, 1994
25. Miyashita T, Krajewski S, Krajewski M, et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994
26. Miyashita T, Reed JC: Tumor suppressor p53 is a direct trascriptional activator of the human bax gene. Cell 80:293-299, 1995
27. Müller-Wieprecht V, Riebeling C, Stooss A, Orfanos CE, Geilen CC: Bcl-2 transfected HaCaT keratinocytes resist apoptotic signals of ceramides, tumor necrosis factor alpha, and 1-alpha, 25-dihydroxyvitamin D(3). Arch Dermatol Res 292:455-462, 2000
28. Nelson MA, Ariza ME, Yang J-M, et al: Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. Cancer Genet Cytogenet 108:91-99, 1999
29. Raisova M, Hossini AM, Eberle J, et al: The bax/bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333-340, 2001
30. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomal MA: Cytokine induction in mice by the immunomodulator imiquimod. J Leukocyte Biol 55:234-240, 1994
31. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC: The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 87:366-371, 2002
32. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME: A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer 74:1482-1486, 1996
33. Schneeberger A, Goos M, Stingl G, Wagner SN: Management of malignant melanoma: New developments in immune and gene therapy. Clin Exp Dermatol 25:509-519, 2000
34. Schön M, Bong AB, Drewniok C, et al: Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138-1149, 2003
35. Sheikh MS, Fornace AJ: Death and decoy receptors and p53-mediated apoptosis. Leukemia 14:1509-1513, 2000
36. Shin MS, Park WS, Kim SY, et al: Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 154:1785-1791, 1999
37. Spruance SL, Tyring SK, Smith MH, Meng TC: Application of a topically-applied immune response modifier, resiquimod gel, to modify the recurrence rate of genital herpes: A pilot study. J Infect Dis 184:196-200, 2001
38. Steinmann A, Funk JO, Schuler G, von den Driesch P: Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43:555-556, 2000
39. Suzuki H, Wang B, Shivji GM, et al: Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 114:135-141, 2000
40. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462, 1995
41. Tomai MA, Gibson SJ, Imbertson LM: Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 28:253-264, 1995
42. Ugurel S, Wagner A, Pföhler C, Tilgen W, Reinhold U: Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 147:621-624, 2002
43. Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA: Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol 119:556-561, 2002
44. Wagner TL, Ahonen CL, Couture AM, et al: Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 191:10-19, 1999
45. Wagner TL, Horton VL, Carlson GL: Induction of cytokines in Cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 9:837-845, 1997
46. Weeks CE, Gibson SJ: Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 14:81-85, 1994
47. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P: Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 164:3961-3970, 2000